Company: AGIO
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0001439222-25-000036
Chunk: 144

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 8
Chunk 144
---
 expenses30,153 31,616 Compensation and related expenses32,990 27,634 Facilities and IT related expenses & other9,600 9,370 Total indirect research and development expenses42,590 37,004 Total research and development expense$72,743 $68,620 

23

Total Research and Development Expenses - Three Months Ended March 31, 2025 vs. Three Months Ended March 31, 2024 – The increase in total research and development expenses of $4.1 million for the three months ended March 31, 2025 compared to the three months ended March 31, 2024 was primarily due to a $5.6 million increase in our indirect expenses, partially offset by a $1.5 million decrease in our direct expenses. The increase in our indirect expenses was primarily due to an increase in compensation and related expenses, driven principally by workforce-related expenses. The decrease in direct expenses was primarily due to a decrease in PYRUKYND® costs due to lower process development expenses, lower costs associated with the phase 3 ENERGIZE and ENERGIZE-T trials and lower costs associated with the phase 3 ACTIVATE-Kids and ACTIVATE-KidsT trials. This was partially offset by an increase in tebapivat costs due to increased costs associated with clinical trials of tebapivat in patients with LR MDS, increased process development expenses and increased costs associated with clinical trials of tebapivat in patients with SCD.

Other Income and ExpenseThree Months Ended March 31,(In thousands)20252024Interest income, net$16,087 $8,889 Other income, net1,253 1,634 

Other Income and Expense - Three Months Ended March 31, 2025 vs. Three Months Ended March 31, 2024 –  The increase in interest income, net in the three months ended March 31, 2025 compared to the three months ended March 31, 2024 was primarily attributable to increased return on our investments and an increased investment balance.

Net LossThree Months Ended March 31,(In thousands)20252024Net loss$(89,289)$(81,549)

Net Loss - Three Months Ended March 31, 2025 vs. Three Months Ended March 31, 2024 – The increase in net loss for the three months ended March 31, 2025